Fischer Medical Ventures Ltd
Fischer Medical Ventures Q2 FY25 earnings call: Revenue & Margins
Q2 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on Fischer Medical Ventures Ltd's Q2 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
The presentation does not provide any specific revenue, sales, or volume figures for the quarter or any year-on-year comparisons. The investor presentation reports the following for the quarter: - EBITDA: ₹36.3 crore, a 45.5% year-on-year increase.
From Fischer Medical Ventures Ltd's Q2 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
2 more points management made on revenue & sales performance
Profitability & Margins
See what Fischer Medical Ventures Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Established manufacturing presence in India in 2022 at Andhra Pradesh Medtech Zone (AMTZ), described as the first and only accredited "Made in India" MRI facility (Page 3, 9).
- Strong sales pipeline of over 100 MRI units across India, MENA, and SEA regions (Page 9).
- Deployment of E-Health Access Points (eHAPs) and kiosks planned at 33,000 schools across India, with a full rollout expected over the next 3-5 years (Page 18).
- No specific capex amounts or detailed budget figures mentioned in the presentation.
2 more points management made on capital expenditure plans
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fischer Medical Ventures Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The presentation mentions a "Strong Sales Pipeline of >100 Units of MRIs across India, MENA and SEA" (Page 9), indicating robust order inflow or pending orders.
- It refers to "Strong order books and expansion into new geographies and product lines" targeted for 2025 (Page 3).
- No specific numeric value for the total order book or order inflow is provided beyond the ">100 Units of MRIs" reference.
2 more points management made on order book & pipeline
Fischer Medical Ventures Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹101 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fischer Medical Ventures Ltd's management said in earlier quarters
Frequently Asked Questions
What were Fischer Medical Ventures Ltd Q2 FY25 results?
The presentation does not provide any specific revenue, sales, or volume figures for the quarter or any year-on-year comparisons. The investor presentation reports the following for the quarter: - EBITDA: ₹36.3 crore, a 45.5% year-on-year increase.
What is Fischer Medical Ventures Ltd share price analysis?
Fischer Medical Ventures Ltd currently shows a neutral. The stock trades at a P/E of 94.6 with a market cap of ₹2,316 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fischer Medical Ventures Ltd planning capital expenditure?
Established manufacturing presence in India in 2022 at Andhra Pradesh Medtech Zone (AMTZ), described as the first and only accredited "Made in India" MRI facility (Page 3, 9).
Keep Fischer Medical Ventures Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.